Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00148902 · ClinicalTrials.gov registry record · Phase 1
Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)
A Phase 1 study of Neoplasms, Breast, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
- 2
- Study locations
NCT00148902 is a Phase 1 study of Neoplasms, Breast that has completed, run by GlaxoSmithKline. The registered enrollment target is 52 participants, below the 1,062-participant average among 9 other Neoplasms, Breast trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00148902, a Phase 1 study of Neoplasms, Breast, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a safety and tolerability study of GW572016 given with docetaxel (TAXOTERE).
Conditions Studied
Interventions
- DRUG docetaxel
- DRUG lapatinib
Study Locations (2)
Michigan
- GSK Investigational Site - Detroit
Tennessee
- GSK Investigational Site - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2003-04-28 |
| Est. Completion | 2006-01-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00148902
The ClinicalTrials.gov registry entry for NCT00148902 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,062-participant average among 9 other Neoplasms, Breast trials with a reported enrollment target (95% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neoplasms, Breast appearing as the primary indexed condition, and to 2 interventions - of which docetaxel is the first listed.
NCT00148902 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Michigan, Tennessee.
Frequently Asked Questions
What is clinical trial NCT00148902 about?
NCT00148902 is a clinical study titled "Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)". This is a safety and tolerability study of GW572016 given with docetaxel (TAXOTERE).
What is the current status of trial NCT00148902?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2003-04-28. Estimated completion is 2006-01-21.
What conditions does trial NCT00148902 study?
This clinical trial studies the following conditions: Neoplasms, Breast.
What interventions are being tested in trial NCT00148902?
The interventions under investigation include: docetaxel (DRUG), lapatinib (DRUG).
Who is sponsoring clinical trial NCT00148902?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00148902 being conducted?
This trial has 2 study locations across Michigan, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms, Breast
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.
COMPLETED · Phase 1
-
A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer
COMPLETED · Phase 1
-
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
ACTIVE NOT RECRUITING · Phase 3
-
Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer
COMPLETED · Phase 3
-
Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC
COMPLETED · Phase 2
-
Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.